<DOC>
	<DOCNO>NCT01826474</DOCNO>
	<brief_summary>The purpose study see whether PRO045 safe effective use medication Duchenne Muscular Dystrophy ( DMD ) patient mutation around location 45 DNA dystrophin protein .</brief_summary>
	<brief_title>Phase IIb Study PRO045 Subjects With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>A phase IIb , open-label , multiple-dose study . The study consist two phase ; dose escalation phase ( subsequent dose-titration ) 48-week treatment phase .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>1 . Duchenne muscular dystrophy result mutation correctable treatment PRO045 confirm stateoftheart DNA diagnostic technique cover DMD gene exon , include limited MLPA ( Multiplex Ligationdependent Probe Amplification ) , CGH ( Comparative Genomic Hybridisation ) , SCAIP ( Single Condition Amplification/Internal Primer ) HRMCA ( HighResolution Melting Curve Analysis ) , correctable PRO045induced DMD exon 45 skipping culture skinderived myoconverted fibroblast . 2 . Ambulant boy age least 5 year day first dose able walk least 230 meter 6 minute walk distance ( 6MWD ) test first screen visit also baseline visit . In addition , 2 3 pretreatment 6MWD test ( screen 1 , screen 2 , baseline ) must within +/30 metre prior first PRO045 administration . 3 . Adequate quality biopsy ( confirm MRI ) lateral head gastrocnemius muscle . An alternative muscle may consider biopsy follow discussion Principal Investigator Prosensa Medical Monitor . 4 . Life expectancy least 3 year inclusion study . 5 . Glucocorticosteroid use stable least 3 month prior first PRO045 administration . Subjects must receive glucocorticosteroids least 6 month prior first PRO045 administration . 6 . Willing able adhere study visit schedule protocol requirement . 7 . Written inform consent sign ( parent ( ) /legal guardian and/or subject , accord local regulation ) . 8 . In France , subject eligible inclusion study either affiliate , beneficiary , social security category . 1 . Known presence dystrophin â‰¥5 % fibres prestudy diagnostic muscle biopsy ( i.e . historic muscle biopsy take prior write inform consent study ) . 2 . Current history liver disease impairment . 3 . Current history renal disease impairment . 4 . At least two aPTT ULN within last month . 5 . Screening platelet count lower limit normal ( LLN ) . 6 . Acute illness within 4 week prior first dose PRO045 may interfere study assessment . 7 . Severe mental retardation behavioural problem opinion investigator prohibit participation study . 8 . Severe cardiomyopathy opinion investigator prohibit participation study . If subject leave ventricular ejection fraction &lt; 45 % screening , investigator discus inclusion subject Medical Monitor . 9 . Expected need daytime mechanical ventilation within next year . 10 . Use anticoagulant , antithrombotics antiplatelet agent . 11 . Use idebenone form coenzyme Q10 within 1 month prior start screen study . 12 . Use nutritional herbal supplement , opinion investigator , may influence muscle performance , within 1 month study . 13 . Use investigational product participation another trial investigational product , within 6 month prior start screen study .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>DMD</keyword>
	<keyword>Prosensa</keyword>
	<keyword>Duchenne</keyword>
</DOC>